Creative Planning decreased its holdings in Crispr Therapeutics AG (NASDAQ:CRSP) by 3.7% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,376 shares of the company’s stock after selling 559 shares during the period. Creative Planning’s holdings in Crispr Therapeutics were worth $589,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in CRSP. Nikko Asset Management Americas Inc. boosted its stake in shares of Crispr Therapeutics by 324.3% in the second quarter. Nikko Asset Management Americas Inc. now owns 1,871,408 shares of the company’s stock worth $88,143,000 after acquiring an additional 1,430,364 shares during the period. ARK Investment Management LLC boosted its stake in Crispr Therapeutics by 34.7% during the second quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock valued at $128,317,000 after buying an additional 701,332 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Crispr Therapeutics by 19.6% during the second quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock valued at $34,801,000 after buying an additional 121,176 shares during the last quarter. Wells Fargo & Company MN boosted its stake in Crispr Therapeutics by 23.9% during the second quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock valued at $28,443,000 after buying an additional 116,540 shares during the last quarter. Finally, Balyasny Asset Management LLC bought a new position in Crispr Therapeutics during the second quarter valued at approximately $5,165,000. 51.09% of the stock is owned by hedge funds and other institutional investors.
Shares of CRSP stock opened at $55.00 on Thursday. Crispr Therapeutics AG has a 1 year low of $22.22 and a 1 year high of $56.16. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. The stock’s 50 day simple moving average is $42.88 and its two-hundred day simple moving average is $44.42.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The business had revenue of $211.93 million for the quarter, compared to the consensus estimate of $6.32 million. As a group, sell-side analysts forecast that Crispr Therapeutics AG will post 0.64 EPS for the current year.
In other news, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the sale, the director now directly owns 7,500 shares in the company, valued at $412,500. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 21.40% of the company’s stock.
A number of equities analysts recently commented on CRSP shares. ValuEngine raised Crispr Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, November 1st. Chardan Capital set a $72.50 price target on Crispr Therapeutics and gave the company a “buy” rating in a research note on Monday, October 21st. BTIG Research increased their price target on Crispr Therapeutics from $51.00 to $59.00 and gave the company a “positive” rating in a research note on Tuesday, July 30th. Canaccord Genuity began coverage on Crispr Therapeutics in a research note on Friday, July 26th. They set a “buy” rating and a $72.00 price target for the company. Finally, Oppenheimer upgraded Crispr Therapeutics from a “market perform” rating to an “outperform” rating and set a $65.00 price objective on the stock in a research report on Tuesday. Two research analysts have rated the stock with a sell rating, four have given a hold rating and eleven have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $57.95.
Crispr Therapeutics Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: What is a Roth IRA?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.